Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...

Denmark’s Prime Minister Mette Frederiksen has called the country’s business leaders to a meeting on Thursday after US ...

He has also threatened Denmark with tariffs if it didn’t sell ... The U.S. is by far Novo Nordisk’s biggest as well as fastest-growing market, where it has marketed its GLP-1 drugs for weight ...

That’s right—the insanely popular diabetes and weight-loss drugs are Danish in origin, from the big pharmaceutical company ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...

Denmark's Prime Minister Mette Frederiksen initiated discussions with business leaders in response to U.S. President-elect ...